FDA Orders St. Jude To Expand Surveillance Of ICD Leads, Including Durata

The agency announced Section 522 post-market surveillance orders that target St. Jude Medical’s recalled Riata leads, as well as the currently marketed Durata leads.

More from Archive

More from Medtech Insight